GlassScriptPhysician profile
Kym M Cannizzaro
NPI 1861912206
$1,390.76
in general payments reported to CMS, 2019-2025
31 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.76 · 2023: $800 · 2024: $379 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $210.97 | 2023 | Xtampza, Belbuca |
| Merz North America, INC. | $131.99 | 2023 | Xeomin |
| Abbvie INC. | $91.92 | 2023 | |
| Sk Life Science, INC. | $90.53 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.76 | 2023-2025 | Xifaxan, Relistor |
| Phathom Pharmaceuticals, INC. | $68.70 | 2024 | Voquezna |
| Edwards Lifesciences Corporation | $62.39 | 2023-2025 | Sapien 3 Ultra Resilia |
| Amgen INC. | $54.08 | 2024-2025 | Evenity, Repatha, Otezla |
| Ibsa Pharma INC. | $52.76 | 2024 | Tirosint, Licart |
| Lilly USA, LLC | $49.89 | 2023-2024 | Jardiance, Zepbound |
| Exact Sciences Corporation | $41.13 | 2025 | The Cologuard Plus Collection Kit |
| Insulet Corporation | $39.73 | 2025 | Omnipod |
| Merck Sharp & Dohme LLC | $38.47 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Averitas Pharma INC. | $33.00 | 2023 | Qutenza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.26 | 2024 | Lifevest |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $27.13 | 2023 | Adlarity |
| Amneal Pharmaceuticals LLC | $26.88 | 2023 | Rytary, Lyvispah |
| Kyowa Kirin, INC. | $26.51 | 2023 | Nourianz |
| Pfizer INC. | $24.33 | 2024 | |
| Ucb, INC. | $22.39 | 2023 | Fintepla |
| Merz Pharmaceuticals, LLC | $20.30 | 2023 | Xeomin |
| Axsome Therapeutics, INC. | $19.58 | 2023 | Sunosi |
| Neurocrine Biosciences, INC. | $19.39 | 2023 | Ingrezza, Ongentys |
| Medtronic, INC. | $17.74 | 2023 | Intellis Adaptivestim |
| E.R. Squibb & Sons, L.L.C. | $17.52 | 2024 | Eliquis |
| Scilex Pharmaceuticals INC. | $16.86 | 2025 | |
| Glaxosmithkline, LLC. | $15.98 | 2024 | Trelegy Ellipta, Arexvy |
| Xeris Pharmaceuticals, INC. | $15.41 | 2025 | Keveyis |
| Verona Pharma, INC. | $14.38 | 2025 | Ohtuvayre |
| Almatica Pharma LLC | $14.02 | 2023 | Loreev Xr |
| International Rehabilitative Sciences, INC | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kym Cannizzaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.